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ABSTRACT 
 
Background: The survival or death of a cell is reliant upon growth factors. Hepatocyte and Epidermal 
Growth Factor (HGF and EGF) promote vital cellular processes such as cell survival, proliferation, 
differentiation, growth, invasion and repair via various pathways. Hence these growth factors facilitate 
normal pregnancy. In complications such as preeclampsia (PE), decreased trophoblast invasion results 
in defective spiral artery remodeling, which leads to decreased blood flow and a hypoxic micro-
environment. In South Africa (SA), HIV infection and PE are the leading causes of maternal mortality 
and morbidity. In light of the high prevalence of HIV infection and PE in SA, this study aimed to 
determine the concentrations of HGF and EGF in HIV associated PE. 
 
Methods:  Post ethics approval, serum samples were collected from normotensive HIV-negative (n = 
20); normotensive HIV-positive (n = 20); preeclamptic HIV-negative (n = 20) and preeclamptic HIV-
positive (n = 20) women. All HIV-positive women received Highly Active Anti-Retroviral Treatment 
(HAART). Quantification and analysis of HGF and EGF expression was attained by using the Bio-Plex 
multiplex immunoassay technique. 
 
Results: As expected there was a statistically significant difference between gestational age, systolic 
and diastolic blood pressures across the study groups (p<0.0001). No significant difference was noted 
in maternal age (p=0.16), parity (p=0.47) and maternal weight (p=0.36) across all study groups. 
  
Irrespective of pregnancy type, HGF was significantly increased in HIV-positive women vs HIV-
negative women (p=0.0225). However, no statistical significance was found based on pregnancy type 
(p=0.8890). A significant decrease of HGF expression was noted between normotensive HIV-negative 
and normotensive HIV-positive women (p=0.0022). 
 
Irrespective of pregnancy type, EGF was found to be significantly elevated in HIV-positive compared 
to HIV-negative women (p=0.0055). In addition, preeclamptic women displayed a higher EGF level 
compared to normotensive women (p=0.003), regardless of HIV status. The Epidermal Growth Factor 
was significantly down-regulated in normotensive HIV-negative group vs normotensive HIV-positive 
(p<0.001), preeclamptic HIV-positive (p<0.001) and preeclamptic HIV-negative groups (p<0.001). 
 
Conclusion 
This novel study displays a significant up-regulation in the expression of HGF and EGF in HIV 
infection during pregnancy, reflecting an immune reconstitution following HAART. These findings 
may be caused due to the HIV accessory protein Tat that inhibits growth factor function thereby, 
negatively impacting cell migration. The up-regulation of EGF expression in PE, may be responsible 
xii 
 
for impaired trophoblast cell invasion. As anticipated in HIV associated PE, EGF expression increased 
in HIV infected pregnancies and PE. The expression Epidermal Growth Factor in HIV associated PE, 
may be used as a risk indicator, predicting PE development prior to the manifestations of clinical signs 
and symptoms. 
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1.0. BACKGROUND AND LITERATURE REVIEW 
 
1.1. Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS)  
The Human Immunodeficiency virus (HIV) attacks the immune system, the body's natural defense 
system to fight diseases. Sub-Saharan Africa accounts for 56% of people living with HIV infection 
globally (Joint United Nations Programme on HIV/AIDS, 2018). In sub-Saharan Africa, women 
account for a disproportionate 59% of HIV infections among adults (aged 15 years and older) in 2017 
(Joint United Nations Programme on HIV/AIDS, 2018). South Africa is home to the largest global HIV 
epidemic (United Nations International Children's Emergency Fund, 2018). The estimated overall HIV 
prevalence rate in SA, is approximately 13,1% (Statistic South Africa, 2018). The province of KwaZulu-
Natal is the global “HIV hotspot” where 40.8% of adults are living with HIV (Bershteyn et al., 2018).  
 
In Africa, at least 3.28 million pregnant women infected with HIV are estimated to give birth each year, 
with more than 75% of these living in sub-Saharan Africa (World Health Organization, 2015).  
Approximately one-fifth of South African women in their reproductive ages (15–49 years) are HIV-
positive (Statistic South Africa, 2018). 
 
The latest Saving Mothers report associates the top three causes of maternal deaths with non-pregnancy 
related infections (such as HIV, tuberculosis, pneumonia) hemorrhages and gestational hypertension, 
of which 83% is attributed to preeclampsia (PE) (Department of Health, 2017). 
 
To date the relationship between HIV infection and PE development remains contradictory. There is 
discord as to whether HIV-infected women are at a lesser, equivalent or advanced risk of developing 
PE than the general population.  Some researchers debate that pregnancy may accelerate the progression 
of HIV to AIDS, whilst others argue that the risk of obstetric complications may be increased due to 
the  HIV-infection (Calvert and Ronsmans, 2013). 
 
 
1.2. Preeclampsia 
1.2.1. Definition 
Preeclampsia (PE) is a pregnancy specific syndrome characterized by high blood pressure (> 140/90 
mmHg) measured on two occasions at least four hours apart and proteinuria (> 300mg/d), occurring in 
the 20th week of gestation (Brown et al., 2018; Maynard and Karumanchi, 2011). It complicates 2-10% 
of pregnancies and is associated with significant maternal and neonatal morbidity and mortality (Backes 
et al., 2011). Globally, PE is one of the main causes of maternal mortality, resulting in about 50 000–
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60 000 deaths annually. In addition, the mother and her child have an increased risk of developing 
cardiovascular complications in the future (Gathiram and Moodley, 2016; O’Tierney-Ginn and Lash, 
2014). 
 
In contrast to a normal pregnancy where there is an altered immune sensitivity, preeclamptic 
pregnancies exhibit an exaggerated immune response (Cerdeira and Karumanchi, 2012).  The placenta 
provides for the exchange of nutrients, gases and waste products between the mother and the baby. The 
proper formation, maturation and maintenance of the placental vasculature is critical, as failure results 
in outcomes such as miscarriage, small for gestational age infants (SGA) and pathological conditions 
such as PE (Cerdeira and Karumanchi, 2012). 
 
1.2.2. Classification of Preeclampsia 
Based on the time of inception of the disease, PE can be divided into two main sub-types, namely early-
onset (EOPE) and late-onset preeclampsia (LOPE). In EOPE, the clinical signs appear at <33 gestational 
weeks, while in LOPE symptoms occur at ≥34 weeks. Majority of preeclamptic pregnancies (>80%) 
fall under the LOPE sub-type (Kovo et al., 2012; Staff et al., 2013).The main pathological difference 
between EOPE and LOPE is fetal growth restriction. Early-onset PE has a higher rate of fetal growth 
restriction than LOPE (Huppertz, 2008; Kovo et al., 2012). 
 
1.2.3. Pathogenesis of Preeclampsia 
The structure involved to maintain and protect the fetus until birth is the placenta. Trophoblast cells 
differentiate into syncytiotrophoblast and cytotrophoblast cells, that connect the fetus to the mother. In 
PE, shallow trophoblast invasion results in incomplete physiological transformation of maternal spiral 
arteries which lead to hypoxic distress, placental insufficiency and fetal malnutrition (Figure 1.1) 
(Naicker et al., 2013). Additionally, there is a decrease in the interstitial cytotrophoblast invasion of the 
myometrium (Gack et al., 2005; Gathiram and Moodley, 2016; Lala and Chakraborty, 2003; Naicker et 
al., 2003). Defects in spiral artery remodeling are restricted to the decidua, where they retain their 
smooth muscle media and elastic lamina (Staff et al., 2013). 
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Figure 1.1. Abnormal placentation in preeclampsia vs normal placental development. (adapted from Lam 
et al. 2005) 
 
Despite intensive research, the pathogenesis and pathophysiology of PE remains poorly understood. 
During the first trimester, the pathogenic process of PE begins long before any clinical signs are noted, 
making it difficult to identify a predictive diagnostic early biomarker. Moreover, there is a dearth of 
information in relation to bioinformatic analysis (Tejera et al., 2012). 
 
Nonetheless, the defective development of placental vasculature is associated with pro-angiogenic 
biomarkers such as Vascular Endothelial Growth Factor (VEGF), angiopoietins and Placental Growth 
Factor (Cerdeira and Karumanchi, 2012). Altered levels of anti-angiogenic factors such as sFlt-1 
compared to pro-angiogenic VEGF is implicated in PE development (Govender et al., 2015). The 
upregulation of sFlt-1 and sEng are directly linked with PE development (Chau et al., 2017; von 
Dadelszen and Magee, 2014). Additionally, the dysregulation of a number of growth factors such as 
Insulin-like Growth Factor (IGF)/Insulin-like-Growth-Factor-Binding Protein (IGFBP), Hepatocyte 
Growth Factor (HGF), Heparin-Binding Epidermal Growth Factor (HB-EGF) and Transforming 
Growth Factor beta (TGF-β) are associated with PE development. Nonetheless, it is still uncertain if 
5 
 
these factors cause an interference with trophoblast invasion, or if their concentration is due to the initial 
failure in trophoblast invasion (Gack et al., 2005). 
 
To-date, the only known treatment of PE is the delivery of the fetus and placenta (Gathiram and 
Moodley, 2016; Romero and Chaiworapongsa, 2013). 
 
 
1.3. Hepatocyte Growth Factor 
The Hepatocyte Growth Factor was initially discovered 30 years ago as a mitogen, affecting 
hepatocytes. Hepatocyte Growth Factor is expressed by cells of mesenchymal origin and acts as a multi-
functional cytokine on cells of epithelial origin (Zarnegar and Michalopoulos, 1995). This specific 
cytokine is produced by stromal cells and it functions to stimulate and regulate epithelial cell growth, 
cell motility, proliferation, morphogenesis and angiogenesis in various tissues and organs via its 
receptor c-Met (Figure 1.2) (Mizuno and Nakamura, 2007). 
 
During embryogenesis, this pleotropic cytokine is produced by the mesenchymal stalk of placental villi 
and is involved in placental growth and expansion (Naghshvar et al., 2013). Trophoblast cells express 
both HGF and its ligand c-Met, which have a paracrine role (Naghshvar et al., 2013).  
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Figure 1.2. HGF binding to c-Met receptor resulting in different biological effects. (adapted from 
Nakamura and Mizuno, 2010) 
 
1.3.1. Hepatocyte Growth Factor in Pregnancy 
In early development, a lack of HGF or damage to the c-Met gene receptor, leads to incomplete 
development of many organs, indicating that HGF signalling is crucial for organ development (Mizuno 
and Nakamura, 2007; Mizuno et al., 2008) 
 
In a normal placenta, a serine residue site at position 985 (Ser-985) in the juxta-membrane of c-Met is 
constitutively phosphorylated and functions as a negative inhibitor for HGF-Met signalling (i.e., switch 
OFF; Figure 1.3). Whilst in animal models, inhibition of HGF production causes placental insufficiency 
and consequential intrauterine demise (Naghshvar et al., 2013). In PE, Ser-985 site is de-phosphorylated 
via recruitment of intracellular protein phosphatase 2A, resulting in the phosphorylation of c-Met 
tyrosine sites and the delivery of pleiotropic activities (i.e., switch ON; Figure 1.3) (Nakamura and 
Mizuno, 2010).  
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Figure 1.3.  HGF and c-Met receptor, illustrating the effect of signalling in PE. (adapted from Nakamura 
and Mizuno, 2010) 
 
Hepatocyte Growth Factor plasma levels are significantly increased during a multitude of organ 
diseases. Several in vitro studies report that HGF has regenerative effects on epithelium in the kidney, 
lung and other tissues such as skin, muscle, cartilage and mucosal repair in the intestine. Hepatocyte 
Growth Factor levels are noticeably increased during liver disease, indicating that HGF production 
occurs by distant organs such as the lung and spleen. Evidence of this is seen during a hepatectomy 
were liver regeneration occurs (Figure 1.4) (Mizuno and Nakamura, 2007; Mizuno et al., 2008; 
Nakamura and Mizuno, 2010). 
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Figure 1.4. Various organs contributing to HGF production to repair liver. (adapted from Nakamura and 
Mizuno, 2010) 
 
In addition, HGF and its c-Met receptor are involved in the pathogenesis of cancer, where it exerts its 
biological properties of invasive growth, tumor proliferation, and angiogenesis (Parikh et al., 2014). 
From this point of view HGF displays vasoactive abilities beside stimulating growth of cells (Morishita 
et al., 1999a). 
 
1.3.2. Hepatocyte Growth Factor in Preeclampsia 
During hypoxia there is a lack of oxygen in tissue cells due to a decrease of local vessels. Hepatocyte 
Growth Factor along with VEGF and basic Fibroblast Growth Factor (bFGF) are secreted to allow the 
formation for new blood vessel thereby, reoxygenating the tissue (Morishita et al., 1999b; Nakamura et 
al., 1996). Thus, local HGF and VEGF systems are positively associated with cardiovascular diseases. 
 
In addition, TGF-β and angiotensin II act together to regulate blood pressure. Although, excessive TGF-
β and/or angiotensin-II interacting with the HGF system, suppresses HGF gene expression in vitro 
(Morishita et al., 1999b). Hence, under chronic injury or hypoxic diseases a down-regulation of HGF 
occurs. As the release of TGF-β or angiotensin-II gradually increases, HGF production is impaired 
therefore various diseases become worse with HGF downregulation (Mizuno and Nakamura, 2007; 
Morishita et al., 1999b; Nakamura and Mizuno, 2010).  
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A marked reduction of local HGF production by TGF-β and angiotensin II treatment has been observed 
(Figure 1.5 and 1.6) ( Yo et al., 1998; Morishita et al., 1999a). 
 
 
 
Figure 1.5. HGF regulation by TGF-β. (adapted from Nakamura and Mizuno, 2010) 
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Figure 1.6. Hypertrophy due to TGF-β and Angiotensin II suppression of HGF. (adapted from Morishita 
et al., 1999a) 
 
Serum HGF (circulating HGF) progressively increases from normotensive to mildly hypertensive 
individuals. Circulating HGF in moderate and severe hypertensives are significantly higher compared 
to normotensive and mild hypertensive individuals. Moreover, hypertensive patients with 
cardiovascular complications have a higher level of serum HGF compared to healthy individuals (Figure 
1.6) (Morishita et al., 1999a; Morishita et al., 1999b). 
 
Therefore, it was concluded that serum HGF concentration cannot be a cause of cardiovascular diseases, 
but rather a potential indicator of hypertension associated with cardiovascular diseases. However, the 
relationship between the HGF and HIV regulatory proteins in HIV associated PE requires clarity (Cele 
et al., 2018; Morishita et al., 1999a). 
 
1.3.3. Hepatocyte Growth Factor in HIV infection 
The role of HGF in HIV infection has not been explored previously, but studies show that the HIV 
accessory Trans-Activator of Transcription (Tat) is involved in the rapid transcription and replication 
of HIV-1 (Romani et al., 2010). 
 
Poggi and Zocchi (2006) report that Tat induces TGF-β transcription, which in turn causes the 
immunosuppression that occurs in HIV/AIDS progression. Studies have also shown that TGF-β causes  
apoptosis in various human cell types during HIV-1 infection (Fittipaldi and Giacca, 2005; Licona-
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Limon and Soldevila, 2007). In addition to the upregulation of TGF-β by Tat, TGF-β is also pleiotropic 
as it reduces anti-apoptotic proteins such as HGF, making cells more susceptible to apoptosis (Romani 
et al., 2010).  
 
There is a paucity of information on the association between HGF and HIV. Nonetheless, HGF 
influences cell proliferation and angiogenesis. In addition, HGF displays mitogenic, motogenic and 
anti-apoptotic properties (Ma et al., 2007). Theron et al. (2017) reported a continuous elevation in 
circulating TGF-β in HIV infection. Figure 1.5 clearly outlines HGF suppression by TGF-β (Nakamura 
and Mizuno, 2010). 
 
 
1.4. Epidermal Growth Factor 
Epidermal Growth Factor (EGF) is a 53-chain amino acid polypeptide with a cytoprotective function, 
that improves survival in preclinical models of sepsis, through its beneficial effect on maintenance of 
cell integrity (Klingensmith et al., 2017). The production of EGF is found at sites in salivary glands, 
the pancreas, and the Brunner’s gland in the duodenum (Kelly et al., 1997; Poulsen et al., 1986). The 
submandibular gland is a rich source of EGF however, EGF also occurs within the general circulation. 
Hormones such as androgens, progestins, and adrenergic agents can increase the production of EGF in 
the submandibular gland and can affect its circulating level (Tsutsumi et al., 1986). 
 
A number of ligands for the EGF Receptor (EGFR) have been identified. These include EGF, Heparin 
Binding EGF, TGF-β, Vacinnia Virus Growth Factor and amphiregulin. Transforming Growth Factor 
is the most frequent ligand for the EGFR in human tissue. After EGF binds to its receptor (EGFR), it 
undergoes dimerization (Harari and Huang, 2001). In the cytoplasm, dimerization triggers tyrosine 
kinase via intermolecular autophosphorylation. Cytoplasmic messenger proteins bind to the 
phosphorylated tyrosine residues stimulating a cascade of signals from the cytoplasm to the nucleus, 
thus triggering a cell response. By-products of EGF binding to EGFR include motility, growth, 
angiogenesis, cell proliferation, invasion, metastasis, cell survival and apoptosis (Harari and Huang, 
2001; Herbst, 2004; Kelly et al., 1997). Due to its function, EGF receptors occur in various tissues in 
the body (Malhotra et al., 2016). A systematic diagram (Figure 1.7) illustrates the events triggered by 
the EGF-EGFR binding process.  
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Figure 1.7. EGF binding to EGF Receptor and initiating a cell response. (adapted from Harari and 
Huang, 2001) 
 
1.4.1. Epidermal Growth Factor in Pregnancy 
Heparin-binding EGF plays an important role during blastocyst implantation and trophoblast invasion 
(Leach et al., 1999). Epidermal Growth Factor also encourages the growth and maturation of different 
tissues and organs such as the gastrointestinal tract, kidney, bone marrow, the anterior pituitary gland 
and lungs (Kasselberg et al., 1985; Kelly et al., 1997). 
 
Epidermal Growth Factor is mitogenic for a number of tissues. In vitro studies report that ethanol affects 
placental EGF function by EGF-induced human chorionic gonadotropin and progesterone secretion 
(Leach et al., 1999; Wimalasena et al., 1994).  
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The EGF family of growth factors thus play an important part of placental growth as an autocrine factor 
in regulating early placental growth and function (Lessey et al., 2002). Epidermal Growth Factor and 
its receptors are expressed in the placenta (Allotey et al., 2017). In addition, animal studies have 
demonstrated that placental growth is suppressed by maternal administration of EGF ant-iserum (Leach 
et al., 2002; Takeda and Iwashita, 1993). The association between EGF and hypertension 
(preeclampsia) has not been demonstrated to-date (Imudia et al., 2008; Klingensmith et al., 2017; 
Lessey et al., 2002; Shah and Catt, 2004).  
 
During pregnancy, syncytialization occurs whereby, numerous molecules such as hormones, cytokines 
and growth factors in the uterine regulate the formation of syncytiotrophoblasts, via various signalling 
cascades. Epidermal Growth Factor, colony stimulating factor (CSF), granulocyte-macrophage colony 
stimulating factor (GM-CSF), leukemia inhibitory factor (LIF), adiponectin and human chorionic 
gonadotropin (hCG) all serve to promote syncytialization whilst TGF-β and Tumor necrosis factor 
(TNF) inhibit syncytialization (Figure 1.8).  
 
 
Figure 1.8. EGF secreted during placentation for placental development and further growth. (adapted 
from Malhotra et al. 2016) 
 
 
1.4.2. Epidermal Growth Factor in Preeclampsia 
Epidermal Growth Factor is needed for proper placentation during pregnancy. In PE, the failure of 
trophoblast cell differentiation and inadequate trophoblast cell migration occurs (Hall et al., 2014).  
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A study by Armant et al. (2015) observed a significant reduction of plasma and trophoblast EGF in 
preeclamptic compared to normotensive women. In addition, they found an overexpression of EGFR to 
which EGF expression is low, hence EGF plays an important role in PE development. Also, EGF 
downregulation can illicit apoptosis since EGF promotes cell survival and regulates cytotrophoblast 
invasion. Bcl-2-associated death promoter (BAD) and caspase-9 (CASP9) are two pro-apoptotic 
molecules that are inhibited by the binding of EGF to its receptor via the Phosphoinositide 3-kinase 
(PI3K) pathway thus, in PE low levels of EGF can cause apoptosis in trophoblast cells (Bergmann, 
2002; Perkins et al., 2002).  
 
1.4.3. Epidermal Growth Factor in HIV infection 
The Tat protein inhibits EGF related cell responses such as cell proliferation, migration, adhesion, cell 
survival, differentiation, and invasion (Fields et al., 2014; Mattila et al., 2005). These processes are due 
to the binding of EGF to EGFR and activation of the PI3K/AKT, RAS/ERK, and JAK/STAT3 pathways 
(Bergmann, 2002; Croker et al., 2008; Sabra et al., 2017; Trusolino et al., 2010). 
 
Tat is also a powerful  angiogenic factor, since it mimics VEGF (Albini et al., 1996). Epidermal Growth 
Factor and VEGF play similar physiological roles in these signalling pathways where they regulate both 
apoptotic and anti-apoptotic proteins, which become dysfunctional in the presence of Tat. This 
effectively blocks the anti-apoptotic pathways leading uncontrollable cell growth (cancer) or enabling 
anti-apoptotic pathways with resultant to cell death (Henson and Gibson, 2006; Li et al., 2009; Limaye 
et al., 2008; Zhang et al., 2015). 
 
 
1.5. Signalling 
Hepatocyte and Epidermal Growth Factor are both part of the same tyrosine kinase family, therefore 
their signalling pathways are identical (Bos et al., 2001; Zhang et al., 2015). Phosphorylation of c-
Met/EGFR with HGF/EGF activates and signals the following pathways, PI3K/AKT/mTOR, 
RAS/ERK, and JAK/STAT3 (Hallberg and Palmer, 2013). This signalling results in the regulation of a 
number of cellular processes such as cell proliferation, motility, angiogenesis, invasion, metastasis, cell 
survival, differentiation, and apoptosis (Chen and Sikic, 2012; Lin et al., 2017; Mertens and Darnell, 
2007). 
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1.6. HIV Associated Preeclampsia 
Immunosuppressive condition such as HIV infection and PE have opposing immune responses 
(Kalumba et al., 2013). In SA, about 30% of antenatal women are infected with HIV. Also, the 
prevalence of PE is approximately 16% (Moodley, 2013).  Thus, SA is an ideal site for studying the 
duality of HIV associated PE. In the province of KwaZulu-Natal, the rate of HIV infection in pregnant 
women is 40% whilst the prevalence of PE is 12% (Panday et al., 2016).  Both HIV infection and PE 
have opposing immune responses. It is plausible to assume that PE associated with HIV infection may 
result in a neutral immune response. However, the prevalence of PE is reduced in untreated HIV infected 
patients, than in those on Highly Active Antiretroviral Therapy (HAART) (Suy et al., 2006). HAART 
re-establishes the maternal immune response, consequently increasing one’s susceptibility to 
developing PE (Govender et al., 2013). 
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1.7. Aim and objectives of this investigation 
To-date a gap exists in PE diagnosis. Hence, research is required to identify predictor tests for the early 
identification of PE development. Therefore, the use of biomarkers in the early detection of 
preeclampsia is promising start.  
 
This study aims:  
To determine the concentrations of HGF and EGF in the pathogenesis of HIV associated normotensive 
versus preeclamptic pregnancy. 
 
The objectives will be: 
-To determine the effect of pregnancy type (normotensive pregnant vs preeclamptic) on HGF and EGF 
regardless of HIV status utilizing a BioPlex Multiplex immunoassay. 
 
- To determine the effect of HIV status (HIV-positive and HIV-negative) on the level of HGF and EGF 
regardless of pregnancy type utilizing a BioPlex Multiplex immunoassay. 
 
-To compare and contrast HGF and EGF across the study population (normotensive HIV-positive, 
normotensive HIV-negative, preeclamptic HIV-positive and preeclamptic HIV-negative). 
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Abstract  
Introduction- Hepatocyte Growth Factor (HGF) and Epidermal Growth Factor (EGF) both 
have tyrosine kinase receptors (c-Met and EGFR) which upon binding, activates and regulates 
many important cellular processes such as cell survival, growth, proliferation, differentiation, 
invasion, repair and so forth via the RAS/MAPK/ERK1/2, PI3K/AKT and JAK STAT3 
pathways. These processes are crucial for the development of a placenta and other functions in 
order for a normal pregnancy to occur. Hence, this study determined the concentrations of HGF 
and EGF to find the correlation between HIV and preeclampsia (PE). 
Material and methods- A total sample size of n=80 was used, n=40 preeclamptic and n=40 
normotensive women these were further stratified into HIV-positive and HIV-negative women. 
Analysis of the growth factors were done by using the Bio-Plex multiplex immunoassay 
method. 
Results- Irrespective of HIV status, based on pregnancy type, EGF in PE women displayed an 
upregulation compared to normotensive women. However, for HGF no significance was found 
between pregnancy type. 
Based on HIV status, regardless of pregnancy type, both HGF and EGF levels were 
significantly increased in HIV-positive women compared to HIV-negative women. 
Across all groups for HGF, significant difference was found between normotensive HIV-
negative (lower) vs normotensive HIV-positive women (higher). 
Nevertheless, for EGF across all groups, a statistically significant decrease was found in 
normotensive HIV-negative women compared to normotensive HIV-positive, preeclamptic 
HIV-positive and preeclamptic HIV-negative women.  
Conclusion- The study demonstrates that there is a strong association between HIV and PE, 
and that HGF and EGF are promising biomarkers to use as a diagnostic tool for PE. 
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Abbreviations – cAMP, 3'-5'-Cyclic adenosine monophosphate; EGF, Epidermal Growth 
Factor; EGFR, Epidermal Growth Factor receptor; ERK, Extracellular signal-regulated 
kinases; HGF, Hepatocyte Growth Factor; HAART, Highly active antiretroviral therapy; HIV, 
Human Immunodeficiency Virus; IQR, Interquartile range; JAK, Janus kinase; MAPK, 
Mitogen-activated protein kinase; Ns, Non-significant; PI3K, Phosphoinositide 3-kinase; PE, 
Preeclampsia; AKT, Protein kinase B; RAS, Renin-angiotensin system; STAT3, Signal 
transducer and activator of transcription 3; Tat, Trans-Activator of Transcription; TGF-β, 
Transforming Growth Factor beta; c-Met, Hepatocyte Growth Factor Receptor; VEGF, 
Vascular Endothelial Growth Factor 
 
Key Message- Preeclampsia and HIV-1 are the two main causes of maternal mortality in South 
Africa. We demonstrate significant differences in HGF and EGF expression in HIV associated 
preeclamptic women, indicating that there is a possible association between preeclampsia and 
HIV. 
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Introduction 
South Africa is home to the largest global human immunodeficiency virus (HIV) epidemic (1). 
In South Africa, 13.1% of the total population is HIV-positive, with one-fifth of women in their 
reproductive ages (15–49 years) being infected (2). Approximately 30% of South African 
parturients are co-infected with HIV (3) with the prevalence being the highest in the province 
of KwaZulu-Natal (37%) (2). Health care professionals providing maternity care are thus faced 
with a severe dilemma. Non-pregnancy related infections (31%), obstetric hemorrhage (24%) 
and hypertensive disorders of pregnancy (19%) are major contributory factors to maternal 
mortality with preeclampsia (PE), accounting for >83% of these deaths (4). Preeclampsia is 
characterized by new onset blood pressure of greater than 140/90 mmHg and proteinuria (> 
300mg/d) after the 20th week of gestation. In KwaZulu-Natal, the prevalence of PE is 12%. 
Notably, maternal deaths from HIV infection and obstetric hemorrhage have declined over the 
period: 2008-2016, however, no change in mortality due to hypertensive diseases in pregnancy 
has occurred (4). 
Whilst the exact cause of preeclampsia has not yet been elucidated, it is characterized by 
inadequate physiological spiral artery remodeling which causes a hypoxic and anti-angiogenic 
micro-environment (5). 
The association between HIV infection and PE is conflicting due to opposing immune 
responses. Moreover, HIV-infected pregnant women treated with Highly Active Anti-
Retroviral Treatment (HAART) have an increased risk for PE development due to the 
reconstitution of their immune system (6). The Hepatocyte Growth Factor (HGF) and 
Epidermal Growth Factor (EGF) belong to a family of receptor tyrosine kinases that are integral 
to the regulation of cell proliferation, survival, differentiation and migration (7). The 
Hepatocyte Growth Factor Receptor (c-Met) also known as tyrosine-protein-kinase-Met, which 
is a proto-oncogene located on chromosome 7q21-31 (8). Its ligand, HGF is converted from an 
inert precursor by a proteolytic cleavage into a bioactive mature form (9). The HGF/c-Met 
binding results in receptor homodimerization and phosphorylation of tyrosine residues that 
mediate a complex signalling network (10). Hepatocyte Growth Factor acts as a pleiotropic 
factor, promoting cell proliferation, survival, motility, differentiation and morphogenesis. 
Since HGF promotes epithelial cell migration and invasion, it could play a pivotal role in 
placentation. In PE, the abnormal trophoblast invasion is associated with a downregulation of 
placental HGF (11). Moreover, during development, the HGF/c-Met receptor interaction is 
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important for organ growth (10, 12). Epidermal Growth Factor acts via the Epidermal Growth 
Factor Receptor (EGFR). Both c-Met and EGFR are transmembrane tyrosine kinases, which 
post binding with their ligand, initiate phosphorylation and activate transcription (13). In 
pregnancy, EGF and its receptor are expressed in the placenta (14). Moreover, the EGFR family 
activate pathways such as the Renin–Angiotensin System/Mitogen-Activated Protein 
Kinase/extracellular signal–regulated kinases 1/2 (RAS/MAPK/ERK1/2), Phosphoinositide 3-
Kinase/Protein Kinase B (PI3K/AKT) and Janus Kinase Signal Transducer and Activator of 
Transcription 3 (JAK STAT-3) (15). Additionally, EGF promotes syncytialization- an integral 
step in blastocyst implantation and placentation and when these processes fail to occur in a set 
sequence, pregnancy complication such as PE occur (5). 
In light of the extensive role played by the tyrosine kinases, HGF and EGF in placentation, the 
aim of this study is to compare the level of serum HGF and EGF in HIV associated 
normotensive pregnant and preeclamptic women using the Bio-plex multiplex immunoassay. 
 
 
Methods and Materials 
Ethical Approval 
This retrospective study received ethical approval from the University of KwaZulu-Natal 
Biomedical Research Ethics Committee (BCA338/17; 17th April 2018). All women were 
recruited from the antenatal clinic of a large regional hospital in Durban, South Africa and gave 
their full informed consent for the participation in this study.  
 
Study population 
The study population (n=80) consisted of 40 normotensive pregnant and 40 preeclamptic 
women. Preeclampsia was defined as a new onset blood pressure of ≥140/90 mmHg and 
proteinuria > 300mg/d after the 20th week of gestation (5).Both groups were further stratified 
by HIV status into preeclamptic HIV-positive (n=20), preeclamptic HIV-negative (n=20), 
normotensive HIV-positive pregnant (n=20) and normotensive HIV-negative pregnant (n=20) 
women. All HIV-positive women received dual HAART and nevirapine therapy, a standard of 
care practice in South Africa. 
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Exclusion criteria for the PE group were eclampsia, chorioamnionitis, chronic diabetes, chronic 
hypertension, pre-existing seizure disorders, intrauterine death, abruption placenta, gestational 
diabetes, systemic lupus erythematous, chronic renal disease, sickle cell disease, thyroid 
disease, cardiac disease, asthma and an unknown HIV status. 
 
Sample type 
Maternal blood samples were collected and centrifuged at 1000g for 10 minutes at 20°C. Serum 
samples were stored at -80°C until required. 
 
ProcartaPlex™ Multiplex Immunoassay method 
A Growth Factor 45-Plex Human ProcartaPlex™ Panel one was performed according to 
manufacturer’s instructions (Invitrogen by ThermoFisher Scientific, catalog no: EPX450-
12171-901). The standards were prepared in a 1:4 dilution series, and no dilution of samples 
were required. 
In a 96 well plate, HGF and EGF capture antibody-coupled magnetic beads were added to each 
well and washed twice. Standards, samples and blanks were then added into their designated 
wells and left to incubate before washing three times. Thereafter, a biotinylated detection 
antibody was pipetted into each well and allowed to incubate. The plate was then washed three 
times before adding streptavidin-phycoerythrin throughout the wells. Finally, the plate was 
washed for a further three times, before resuspending each well with assay buffer. The plate 
was then ready to be placed into the Bio-Plex system for reading. 
The Bio-Plex®MAGPIXTM Multiplex Reader (Bio-Rad Laboratories Inc., USA) was utilized 
to read the experiment plate. Bio-Plex ManagerTM software version 4.1 was used to obtain the 
data from the multiplex analysis.   
  
Statistical Analysis  
Data analysis was performed using Graphpad Prism 5.00 for Windows (GraphPad Software, 
San Diego California USA). The Kolmogorov Smirnov test for normality revealed non-
parametrically distributed data. A Mann-Whitney U test was utilized to determine statistical 
significance according to pregnancy type (preeclamptic vs normotensive) and HIV status 
(positive vs negative). Results are represented as median and interquartile range (IQR). To 
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determine statistical significance across all groups, a Kruskal-Wallis test in combination with 
the Dunn’s Multiple comparison post hoc test was used. Statistical significance was P ˂ 0.05. 
Results  
Patient Demographics and Clinical Characteristics 
Patient demographics and clinical characteristics are represented in Table 1 as median and 
interquartile range (IQR). No significant differences were reported in maternal age (P=0.16), 
parity (P=0.47) and maternal weight (P=0.36), across all study groups. However, there was a 
statistically significant difference between gestational age, systolic and diastolic blood 
pressures across the study groups (P<0.0001).  
 
Table 1. Patient demographics across study groups (n=80) 
  
Normotensive 
HIV Negative  
Normotensive 
HIV Positive  
Preeclamptic 
HIV Negative               
Preeclamptic 
HIV Positive                   
P-value 
Maternal Age (years) 24.50 (9.75) 28.50 (9) 24.00 (9.5) 29.00 (10) 0.1601 (ns) 
Gestational Age (weeks) 39.00 (3) 38.00 (3) 32.00 (11) 32.00 (6) <0.0001 *** 
Parity 1.00 (2) 1.50 (1) 1.00 (1.750) 1.00 (1) 0.4707 (ns) 
Systolic BP (mmHg) 121.5 (16.2) 110.0 (18.5) 158.5 (17) 157.5 (22.3) <0.0001 *** 
Diastolic BP (mmHg) 73.0 (13.75) 70.0 (7.25) 103.5 (19.5) 100.5 (13) <0.0001 *** 
Weight (kg) 76.5 (16.23) 79.5 (19.02) 70.0 (16.17) 79.0 (35.97) 0.3557 (ns) 
Results are represented as the median (IQR), ns = non-significant,  
* P < 0.05   
*** P < 0.001 
 
Serum concentrations of Hepatocyte Growth Factor 
Pregnancy type- The concentration of HGF was not statistically different between the 
normotensive pregnant (median = 6.91pg/ml, IQR = 20.43pg/ml) vs preeclamptic (median = 
8.03pg/ml, IQR = 9.63pg/ml) groups, regardless of HIV status (Mann-Whitney U = 382.5; P = 
0.889; Figure 1A). 
HIV status- However, there was a significant difference in HGF level between the HIV-positive 
(median = 10.68pg/ml, IQR = 21.1pg/ml) vs HIV-negative (median = 6.44pg/ml, IQR = 
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6.35pg/ml) groups, irrespective of pregnancy type, (Mann-Whitney U = 252.0; P = 0.0225; 
Figure 1B).  
Across all groups- There was a significant difference in HGF concentration between 
normotensive HIV-negative (median = 4.17pg/ml, IQR = 5.89pg/ml) vs normotensive HIV-
positive (median = 21.78pg/ml, IQR = 24.74pg/ml) pregnant women (Kruskal-Wallis H = 
14.63; P = 0.0022; Figure 1C). No differences were noted across all other groups. 
 
 
1A 
 
 
 
 
1B 
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Figure 1. Hepatocyte Growth Factor: (A) Preeclamptic vs Normotensive Groups, (B) HIV infected 
vs HIV uninfected groups, (C) Across All Groups. *Serum concentrations of HGF are 
significantly different between HIV-positive and HIV-negative group, P = 0.0225. **Serum 
concentrations of HGF are significantly different between normotensive HIV-positive and 
normotensive HIV-negative group, P = 0.0022. 
 
Serum concentrations of Epithelial Growth Factor  
Pregnancy type- EGF expression was statistical different between the normotensive pregnant 
(median = 38.82pg/ml IQR = 63.63pg/ml) vs preeclamptic (median = 93.13pg/ml, IQR = 
62.3pg/ml) groups, irrespective of HIV status (Mann-Whitney U = 186.0; P = 0.0003; Figure 
2A).  
HIV status- The concentration of EGF was significantly different between the HIV-positive 
(median = 88.85pg/ml, IQR = 73.14pg/ml) vs HIV-negative (median = 49.64pg/ml, IQR = 
72.73pg/ml) groups, regardless of pregnancy type (Mann-Whitney U = 241.5; P = 0.0055; 
Figure 2B).  
Across all groups- A statistically significant difference in EGF concentration was noted 
between: normotensive HIV-negative (median = 17.04pg/ml, IQR = 30.88pg/ml) vs 
normotensive HIV-positive (median = 72.25pg/ml, IQR = 59.88pg/ml); normotensive HIV-
negative (median = 17.04pg/ml, IQR = 30.88pg/ml) vs preeclamptic HIV-positive (median = 
96.36pg/ml, IQR = 80.81pg/ml) and normotensive HIV-negative (median =17.04pg/ml, IQR = 
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30.88pg/ml) vs preeclamptic HIV-negative groups (median =86.42pg/ml, IQR =59.50pg/ml), 
(Kruskal-Wallis H = 25.98; P < 0.0001; Figure 2C).  
 
 
2A 
 
 
 
 
2B 
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Figure 2. Epidermal Growth Factor: (A) Preeclamptic vs Normotensive Groups, (B) HIV infected 
vs HIV uninfected groups, (C) Across All Groups. ***Serum concentrations of EGF are 
significantly different between preeclamptic and normotensive group, P = 0.0003. **Serum 
concentrations of HGF are significantly different between HIV-positive and HIV-negative group, 
P = 0.0055. ***Serum concentrations of EGF are significantly different between normotensive 
HIV-positive and normotensive HIV-negative group, P < 0.0001. ***Serum concentrations of 
EGF are significantly different between preeclamptic HIV-negative and normotensive HIV-
negative group, P < 0.0001. ***Serum concentrations of EGF are significantly different between 
preeclamptic HIV-positive and normotensive HIV-negative group, P < 0.0001.  
 
Table 2. Serum concentration (pg/ml) of Growth Factors across all study groups 
 
Normotensive  Preeclamptic P value 
 
HIV Negative 
(n=20) 
HIV Positive 
(n=20) 
HIV Negative 
(n=20) 
HIV Positive 
(n=20) 
 
EGF 17.04 (30.88) 72.25 (59.88) 86.42 (59.50) 96.36 (80.81) < 0.0001 
HGF 4.17 (5.89) 21.78 (24.74) 8.03 (11.75) 8.17 (7.01) 0.0022 
Results are represented as median (interquartile range) 
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Discussion  
Hepatocyte Growth Factor: This study demonstrates that serum HGF concentrations were 
similar between normotensive and PE pregnancies, regardless of the HIV status (Figure 1A). 
Several studies also report similar serum HGF levels between PE and normotensive 
pregnancies (16). It is plausible that sample type affects HGF as contradictory studies report a 
statistically significant increase in the plasma HGF concentration in PE (17). Martinez-Fierro 
et al. (18) noted that the urinary concentration of HGF at 20 weeks gestation were elevated in 
women that developed PE compared to normotensive pregnancy; suggesting that urinary HGF 
could possibly have predictive test value for the diagnosis of PE (18). 
It is noteworthy to hypothesize that a high production of HGF causes saturation of HGF 
receptor (c-Met), which results in a reduced level of the free circulating HGF in blood. 
Nonetheless, Naghshvar et al. (19) investigated c-Met levels in both serum and plasma and 
found that c-Met levels correlated with severity of PE. 
Both HGF and EGF are tyrosine kinases which activate signalling to mediate cell proliferation, 
differentiation, angiogenesis, migration and invasion via the JAK STAT-3 and MAPK/ERK1/2 
pathways, proliferation and survival via PI3K/AKT cascade (12). The c-Met receptor 
significantly regulates the activation of cell differentiation, proliferation and self-renewal via 
the MAPK/ERK1/2 pathway (20). In PE, there is a dysregulation of the latter pathway (20). 
This reduced HGF/c-Met axis inhibits trophoblast cell differentiation, proliferation and 
repair/regeneration of trophoblast cells and may explicate the reduction in trophoblast cell 
migration that occurs in PE (12). A recent study by Zeng et al. (21) indicated that HGF was 
responsible for placental growth and that inhibition of HGF production in an animal model 
resulted in stillbirth. 
The reduction of HGF, albeit non-significantly in PE in the current study may be attributed to 
the hypoxic micro-environment. Hypoxia has been shown to reduce HGF expression, thereby 
limiting interaction with the c-Met receptor on trophoblast cells (22). This receptor ligand 
binding restricts trophoblast 3′,5′-cyclic adenosine monophosphate (cAMP) expression which 
activates protein kinase A/ Ras-proximate-1 (PKA/RAP1). Subsequently, Serine/threonine-
protein kinase (PAK) is inappropriately stimulated leading to integrin β1 down-regulation (23), 
eventuating in decrease trophoblast invasion (Figure 3). 
Furthermore, c-Met is known for its ability to elicit a cell survival response (anti-apoptotic) via 
the PI3K/AKT pathway. Hepatocyte Growth Factor is needed to regulate this anti-apoptotic 
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response. In a previous report, our research group demonstrated elevated apoptosis of 
trophoblast cells in PE (24). Thus, it is plausible that the decline of serum HGF accounts for 
the increased apoptosis of trophoblast cells, with resultant decline in trophoblast 
invasion/migration in PE (22). 
Our study also illustrated an elevated serum concentration of HGF in HIV-positive women 
compared to that of HIV-negative women (Figure 1B), irrespective of pregnancy type. Tulasne 
et al. (25) established that stress stimuli transform the anti-apoptotic function of the c-Met 
receptor to a pro-apoptotic function by a caspase-dependent cleavage. Both PE and HIV 
infection are well accepted stress stimulant conditions (26). 
In an in vitro study, the HIV accessory protein, Trans-Activator of Transcription (Tat) is able 
to activate the intrinsic pathway of apoptosis (27). Tat induces an upregulation of Transforming 
Growth Factor beta (TGF-β) which inhibits HGF production, thus negating its pleiotropic 
actions (28). Moreover, Wiercińska-Drapalo et al. (29) noted that TGF-β levels are greater than 
twofold in the HIV-positive compared to HIV-negative women. Despite the lack of correlation 
between HAART and TGF-β in the latter study, HAART is believed to be advantageous during 
early stages of therapy, with positive HGF production and hepatocyte survival (30). In the 
current study, we noted a significantly different HGF concentration between normotensive 
HIV-positive vs normotensive HIV-negative women (Figure 1C). It is plausible that a 
compromised immune system elicits a compensatory response to produce HGF in order to 
repair tissues and organs damaged by the HIV infection (31). 
Epidermal Growth Factor: Our study also demonstrated an up-regulation of serum EGF in 
preeclamptic compared to normotensive pregnancies (Figure 2A), regardless of HIV status. 
This finding is corroborated by Armant et al. (32), who reported that EGFR an EGF receptor 
protagonist, is also overexpressed in PE (32). Notably, EGFR initiates signal transduction 
cascades namely the MAPK, AKT and JAK-STAT-3 pathways. This signalling initiates DNA 
synthesis by modifying cell migration, adhesion, and proliferation. Thus, it is possible that the 
deficient trophoblast cell invasion in PE may be a result of an aberrant signal transduction 
cascade emanating from the dysregulation of EGFR-EGF binding (7). Ferrandina et al. (33) 
further hypothesized that the hypertensive disorders of pregnancy are related to increased 
placental EGFR concentration. In contrast to our findings, plasma EGF levels were reported to 
be twofold higher in normotensive pregnant compared to PE women (32). 
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Epidermal Growth Factor signals via the JAK STAT-3 pathway highlighting the fact that EGF 
influences proliferation and invasion of trophoblast cells (34). The PI3K/AKT pathway has 
been associated with many cellular processes such as regulation of the cell cycle, cell death, 
adhesion, migration and metabolism. Notably, a decrease in EGF reduces AKT 
phosphorylating of Bcl-2-associated death promoter (BAD), which leads to trophoblast cell 
death in PE (35). In PE, the invasive trophoblast cells exit the cell cycle in the G1 phase, leading 
them to apoptosis rather than passing through into the S phase and mitosis (24). 
In this study, EGF was elevated in HIV-positive compared to HIV-negative women (Figure 
2B), irrespective of pregnancy type. It is plausible that an immunocompromised milieu may 
affect EGF-EGFR interactions. Burgel and Nadel (36) correlated this upregulation of EGF with 
an exaggerated innate immune response. 
Additionally, preeclampsia is characterized by impaired angiogenesis (24). The HIV accessory 
protein Tat is a powerful angiogenic factor, in that it mimics Vascular Endothelial Growth 
Factor (VEGF) (37). The Tat protein inhibits EGF-induced processes such as cell proliferation, 
differentiation, invasion, migration, adhesion and cell survival (38). Therefore, apart from Tat 
affecting angiogenesis, it can also affect trophoblast cell migration. In HIV-positive women, 
Tat would reduce the predisposition to PE development (39). Since Tat inhibits EGF function, 
it would negatively impact trophoblast cell migration. 
An association between HGF and EGF signalling has been established by Zhang et al. (40), 
where upon activation, these growth factors elicit the same cellular responses (Figure 3). The 
binding of HGF or EGF to their respective receptors induce phosphorylation of PI3K which 
activates AKT, IκB kinase (IKK) and inhibits Caspase-9/BAD, thus mediating pro-apoptosis. 
Activation of AKT regulates mammalian target of rapamycin (mTOR) which is responsible for 
cell survival and proliferation. In addition, IKK promotes nuclear factor kappa-light-chain-
enhancer of activated B cells (Nf-KB) which triggers cell invasion, adhesion, proliferation and 
angiogenesis (41) (Figure 3). 
The activation of STAT-3 via JAK is a byproduct of the fusion between HGF/EGF and c-
Met/EGFR (Figure 3). This signalling results in the regulation of a number of cell responses, 
such as: cell growth, differentiation, invasion, repair and self-renewal (34). 
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Figure 3. Cross link in PI3K/AKT, MAPK/ERK1/2 AND JAK STAT-3 pathways between 
HGF/EGF upon activation. (adapted from Zhang et al. (40)) 
The docking of HGF/EGF to their ligands results in phosphorylation of Growth factor receptor bound 
protein 2 /Son of Sevenless (Grb2/SOS). In addition, cAMP/PKA/RAP1 are also phosphorylated, in 
which both promote the RAS pathway (23). Henceforth Rapidly Accelerated Fibrosarcoma- Mitogen-
activated protein kinase (RAF-MEK-ERK1/2) cascade is stimulated eliciting cell growth, proliferation 
and cell cycle regulation. RAS also triggers the Ras-related C- ρ - Serine/threonine-protein kinase 
(RAC-RhO-Pak) pathway which initiates integrin β1 upregulation for cell migration, adhesion and 
motility (42). 
 
 
One of the limitations of this study is the absence of viral load, which subsequently resulted in 
no correlation between HGF/EGF based on severity of HIV infection. In addition, all HIV-
positive women were on highly active anti-retroviral treatment, which may have confounded 
both HGF and EGF levels. Lastly, the heterogeneity of our study population, which was not 
stratified into early and late onset PE, could be seen as a limitation.  
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Conclusion 
This study demonstrates a significant increase of EGF in the oxidative stressed micro-
environment of PE compared to normotensive women, regardless of HIV status. In addition, a 
significant up-regulation of HGF and EGF was found in HIV infected women, irrespective of 
pregnancy type. Off-note, the HIV accessory protein affects angiogenesis, cell signalling and 
trophoblast cell migration. Furthermore, HAART may be implicated in the elevation of EGF 
and HGF in HIV infection. It is thus plausible that EGF may have possible predictor indicator 
test value for the early detection of PE. 
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3.0. SYNTHESIS 
 
The main cause of maternal deaths worldwide are hemorrhage, PE and infections due to poor medical 
infrastructure (Pasha et al., 2018). Throughout the world PE complicates approximately 7% to 10% of 
pregnancies (Kalumba et al., 2013). The repercussion of this leads to an unwanted escalation of 
mortality and morbidity rates globally. In Kwa-Zulu-Natal, SA the incident rate for PE is 12% 
(Department of Health, 2017). 
 
South Africa also has the highest HIV prevalence in the world with 7.1 million infected individuals 
(Statistic South Africa, 2018). This immunosuppressant disorder is found in 30% of pregnant women 
in SA, such a condition may complicate a pregnancy in various ways namely PE (Moodley, 2013). The 
compromised immune system in HIV infection would neutralize the exaggerated immune response by 
PE.  
 
Preeclampsia is categorized by having an elevated blood pressure in conjunction with proteinuria 
occurring within the second trimester and onwards (Brown et al., 2001). The exact pathophysiology of 
PE requires clarity. In contrast to a normal pregnancy, the placentation process is defective in PE as 
cytotrophoblast cells fail to invade the endometrial wall (Romero and Chaiworapongsa, 2013). As a 
result of a limited decidual spiral artery remodeling blood flow to the fetus is restricted (Brosens et al., 
2011). Early diagnostic tests for PE development do not exist at this moment nevertheless, there have 
been promising biomarkers used to indicate PE such as Insulin-like Growth Factor, EGF, HGF, VEGF, 
TGF-β, etc. (Gack et al., 2005). However, to date no studies have reported HGF and EGF expression 
in HIV associated PE. 
 
In this study HGF and EGF were investigated due to their cell function in apoptosis, invasion, adhesion, 
cell proliferation, survival, motility, differentiation and morphogenesis (Boon et al., 2002; Zhang et al., 
2015). During placentation, EGF facilitates implantation of the blastocyst and together with cytokines 
maintain placental function in normal pregnancy (Malhotra et al., 2016).  
 
Hepatocyte Growth Factor is also responsible for maintaining normal blood pressure via a chain 
reaction effect of TGF-β, a well-known causative component of hypertension in the renin-angiotensin-
aldosterone system (RAAS) (Matsuki et al., 2014). High, consistent levels of TGF-β suppress HGF 
production (Choi et al., 2018; Morishita et al., 1999b). In pregnancy, during fetal development HGF is 
required for differentiation of cells into tissue which is important for fetal organ development (Mizuno 
et al., 2008). In light of the high prevalence of HIV infection and PE in SA and the role of HGF and 
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EGF in the cell cycle, this study evaluates serum HGF and EGF in HIV infected preeclamptic women 
using the Multiplex Immunoassay method (Nakamura and Mizuno, 2010). 
 
 
3.1. Pregnancy type 
The results of this study demonstrated no difference of HGF levels in preeclamptic compared to 
normotensive pregnant women, irrespective of their HIV status. This finding is in line with (Horibe et 
al., 1995). In contrast, a later study by Charkiewicz et al. (2018) reported an upregulation of plasma 
HGF in preeclamptic vs normotensive women. Furthermore,  Naghshvar et al. (2013) found that the 
levels of c-Met was lower in PE compared to normal pregnancies and varied with the severity of the 
disorder, implicating fewer receptor-ligand binding. (Naghshvar et al., 2013). 
 
In contrast to HGF, a significant up-regulation of EGF expression was observed in preeclamptic 
compared to normotensive pregnant women irrespective of HIV infection. However, opposing results 
were noted by Armant et al. (2015) who found a two-fold elevation of EGF in normotensive compared 
to PE. Epidermal Growth Factor activates the JAK STAT-3 and MEK ERK1/2 pathways and promotes 
trophoblast cell invasion, migration, proliferation and cell growth; vital steps that ensure a successful 
pregnancy (Bass et al., 1994; Gupta et al., 2017). Furthermore, a down-regulation of both HGF and 
EGF promotes  trophoblast apoptosis via the PI3K/BAD pathway (Humphrey et al., 2008). Epidermal 
Growth Factor and HGF down-regulation will inhibit cell adhesion, invasion and proliferation, 
processes essential for normal placentation (Mattila et al., 2005; Mizuno et al., 2008). 
 
 
3.2. HIV status 
In this study, HGF was enhanced in HIV-positive women, irrespective of pregnancy type. Notably, the 
HIV-1 accessory protein, trans-activator of transcription (Tat) favors the production of TGF-β which 
suppresses HGF production (Choi et al., 2018; Morishita et al., 1999b; Xu et al., 2017).  Similarly, EGF 
was up-regulated by HIV status regardless of pregnancy type. It is a standard of practice in SA to 
administer HAART to all HIV infected pregnant women. HAART promotes immune reconstitution 
(Wimalasundera et al., 2002). Nonetheless, HAART also promotes HGF production ensuring 
hepatocyte survival in cancer (Sonderup and Wainwright, 2017). This suggests that HAART will favour 
HGF and EGF production (Theron et al., 2017). 
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3.3. Hepatocyte Growth Factor - Across the groups  
Normotensive HIV-positive vs normotensive HIV-negative- Across the groups there was a significant 
up-regulation of HGF in normotensive HIV-positive women in comparison to normotensive HIV-
negative women. The enhanced HGF level in HIV-positive women is attributed to HAART. Previous 
literature suggests that HIV is a stress stimulant (Chaturvedi et al., 2018) and oxidative stress up-
regulates HGF (Organ and Tsao, 2011; Tulasne et al., 2004). The increase in HGF promotes cell 
survival via the PI3K/BAD pathway (Ozaki et al., 2003).  
 
 
3.4. Epidermal Growth Factor - Across the groups 
Normotensive HIV-positive vs normotensive HIV-negative- We report a significant increase of EGF 
across the groups, in normotensive HIV-positive women compared to normotensive HIV-negative 
women. In HIV infected women it is found that HIV is the main cause for chronic oxidative stress. 
Similar to the above interrogation, stress leads to increased HIV viral replication, increased apoptosis 
and deteriorating immune functions (Pace and Leaf, 1995; Tang and Smit, 2000). In response to cellular 
stresses the JAK STAT-3 and MEK ERK1/2 pathways are activated by EGF to counteract the effect of 
oxidative stress (Tong et al., 2014).  
 
Preeclamptic HIV-negative vs normotensive HIV-negative- There was also a statistical upregulation of 
EGF in preeclamptic HIV-negative women in contrast to normotensive HIV-negative women. 
Preeclampsia is a result of placental hypoxia (Verma et al., 2018). The presence of continuous hypoxia 
leads to oxidative stress because of the imbalance caused  between reactive oxygen species and 
antioxidants (Schoots et al., 2018). A study by Kothari et al. (2003) showed that cell death induced by 
hypoxia could be avoided by administration of EGF. Hence in PE, EGF production is increased due to 
the oxidative stress caused by the hypoxic micro-environment. 
 
Preeclamptic HIV-positive vs normotensive HIV-negative- Furthermore, a noteworthy rise in EGF was 
found in preeclamptic HIV-positive women compared to normotensive HIV-negative women. The 
elevation of EGF may be attributed to the oxidative stress occurring both in PE and in HIV infection. 
HAART endorses EGF up-regulation (Theron et al., 2017). Nevertheless, a patient who presents with 
oxidative stress becomes stress-responsive (Matsuda et al., 1998) by producing EGF to promote the 
PI3k/AKT, JAK STAT-3 and MEK ERK1/2  pathways to protect against stress induced cell death 
(Trachootham et al., 2008; Wang et al., 2000). 
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3.5. Limitations 
A limitation of this study is that all HIV infected women received HAART. In addition, the duration of 
HAART is unavailable. The lack of stratification of our groups by gestational age may have influenced 
analyte expression.  
 
 
3.6. Conclusion  
This novel study demonstrates a significant increase in the expression of HGF and EGF in HIV infection 
regardless of pregnancy type, reflecting an immune reconstitution following HAART. This finding may 
be attributed to the HIV accessory protein Tat that inhibits growth factor function thereby, negatively 
impacting cell migration. Hepatocyte Growth Factor was unexpectedly found to be similar between 
pregnancy types; it may be plausible that both HAART and TGF-β synergistically work together to 
neutralize HGF production. The up-regulation of EGF expression in preeclampsia may be responsible 
for impaired trophoblast cell invasion mediated by dysregulation of cell signalling pathways. As 
expected in HIV associated PE, EGF expression declined by HIV status and pregnancy type. Epidermal 
Growth Factor expression has potential use as a diagnostic risk indicator for preeclampsia development 
prior to the onset of maternal signs and symptoms. 
 
Future direction requires studies with a larger sample size, sub-grouping by gestational age across the 
trimesters of pregnancies. 
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Appendix 2 – Standard curve HGF 
 
 
  
Regression Type: Logistic - 5PL
Std. Curve: FI = -4.91983 + (14469.2 + 4.91983) / ((1 + (Conc / 12445.5)^-1.10538))^0.822956
FitProb. = 0.0984, ResVar. = 2.3189
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Appendix 3 – Standard curve EGF 
 
Regression Type: Logistic - 5PL
Std. Curve: FI = -4.49858 + (14899.6 + 4.49858) / ((1 + (Conc / 840.719)^-1.1409))^0.87148
FitProb. = 0.0129, ResVar. = 4.3518
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